HealthyNCT03046940
The Influence of Doctor-patient Communication on Patients' Willingness to Take Medication
A study testing Patient-centered style of communication and Doctor-centered style of communication in people with Healthy, run by Philipps University Marburg at 1 site in Germany.
Trial summary
The experiment aims at investigating whether the doctor-patient communication has an influence on patients' willingness to take medication. Patients' attitude towards the medication is manipulated via a critical film sequence. Read more about this study
- Who is it for?
- Ages 18 to 35 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Patient-centered style of communication and Doctor-centered style of communication
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteGermany
- Study dates
- 15 Mar 2017to 8 Jun 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- female
- between 18 and 35 years
- healthy
- adequate ability to see
- fluent in German (reading and writing)
Who cannot join
- regular intake of cognitive enhancers/medication that enhances concentration
- intake of psychotropic drugs
- medical or pharmacy students, advanced psychology students
- participants who know the investigators
Trial locations and contacts
1 site in 1 country.
Germany1 site
Department of Clinical Psychology and Psychotherapy, Philipps-University Marburg
Marburg, 35032
About this study
The experiment aims at investigating whether the doctor-patient communication has an influence on patients' willingness to take medication. Patients' attitude towards the medication is manipulated via a critical film sequence. Afterwards patients of the two experimental groups have a communication with one of the investigators of the study. Patients are told that the investigator is a medical doctor. The "doctors" either communicate in a patient-centered or doctor-centered style with the patient. Patients in the control group do not have the possibility to talk to a "medical doctor". Afterwards patients are offered the aforementioned pill that is supposed to be a cognitive enhancer (actually placebo pill). Pill intake is voluntary. The investigators hypothesize that patients in the experimental group with the patient-centered style of communication are more likely to take the pill than patients in the experimental group with the doctor-centered style of communication or patients in the control group.
- Conditions
- Healthy
- Being tested
- Patient-centered style of communication, Doctor-centered style of communication
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Patient-centered style of communicationOther
Different doctor-patient communication
Doctor-centered style of communicationOther
Different doctor-patient communication
| Study group | Role | What they receive |
|---|---|---|
| Control group | No intervention | No communication with a doctor |
| Patient-centered | Experimental | Participants communicate with a doctor that uses a patient-centered style of communication Receives: Other: Patient-centered style of communication |
| Doctor-centered | Experimental | Participants communicate with a doctor that uses a doctor-centered style of communication Receives: Other: Doctor-centered style of communication |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pill intake
Behavioural test
Measured: Within 10 minutes after doctor-patient communication
Secondary outcomes (3)
Willingness to take medication (VAS)
Visual analogue scale (VAS)
Measured: Within 10 minutes prior to watching the film sequence, directly (within 5 minutes) after the film sequence, directly (within 10 minutes) after doctor-patient communication
Critical attitude towards the medication (VAS)
Visual analogue scale (VAS)
Measured: Within 10 minutes prior to watching the film sequence, directly (within 5 minutes) after the film sequence, directly (within 10 minutes) after doctor-patient communication
Influence on concentration (Concentration task)
Concentration task
Measured: Directly (within 10 minutes) after the pill was offered
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Feb 2017 (estimated)
- Study start15 Mar 2017
- Primary completion8 Jun 2017
- Study completion8 Jun 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 120 participants (actual)
Sponsor and investigators
- Lead sponsor
- Philipps University Marburg
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Winfried Rief, Philipps University Marburg
- Investigators
- Winfried Rief, PhD, Prof, Principal investigator, Philipps University Marburg
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03046940
- Sponsor's protocol ID
- 2016-37v-r
- Status last verified
- Jun 2017
- First submitted
- 30 Jan 2017
- Last updated
- 9 Jun 2017
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Jun 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Influence of Doctor-patient Communication on Patients' Willingness to Take Medication
- ClinicalTrials.gov ID
- NCT03046940
- Acronym / sponsor ID
- 2016-37v-r
- Conditions
- Healthy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 120 participants (actual)
- Lead sponsor
- Philipps University MarburgUniversity, hospital or other
- Study start
- 15 Mar 2017 (actual)
- Primary completion
- 8 Jun 2017 (actual)
- Study completion
- 8 Jun 2017 (actual)
- First posted
- 8 Feb 2017 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The experiment aims at investigating whether the doctor-patient communication has an influence on patients' willingness to take medication. Patients' attitude towards the medication is manipulated via a critical film sequence. Afterwards patients of the two experimental groups have a communication with one of the investigators of the study. Patients are told that the investigator is a medical doctor. The "doctors" either communicate in a patient-centered or doctor-centered style with the patient. Patients in the control group do not have the possibility to talk to a "medical doctor". Afterwards patients are offered the aforementioned pill that is supposed to be a cognitive enhancer (actually placebo pill). Pill intake is voluntary. The investigators hypothesize that patients in the experimental group with the patient-centered style of communication are more likely to take the pill than patients in the experimental group with the doctor-centered style of communication or patients in the control group.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Control group | No intervention | –No communication with a doctor |
| Patient-centered | Experimental | Other: Patient-centered style of communicationParticipants communicate with a doctor that uses a patient-centered style of communication |
| Doctor-centered | Experimental | Other: Doctor-centered style of communicationParticipants communicate with a doctor that uses a doctor-centered style of communication |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- female
- between 18 and 35 years
- healthy
- adequate ability to see
- fluent in German (reading and writing)
Key exclusion criteria (4 listed)
- regular intake of cognitive enhancers/medication that enhances concentration
- intake of psychotropic drugs
- medical or pharmacy students, advanced psychology students
- participants who know the investigators
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Patient-centered style of communicationDifferent doctor-patient communication | Other | Patient-centered |
| Doctor-centered style of communicationDifferent doctor-patient communication | Other | Doctor-centered |
Primary outcome
Pill intake
Time frame: Within 10 minutes after doctor-patient communication
Behavioural test
3 secondary outcomes
Willingness to take medication (VAS)
Time frame: Within 10 minutes prior to watching the film sequence, directly (within 5 minutes) after the film sequence, directly (within 10 minutes) after doctor-patient communication
Critical attitude towards the medication (VAS)
Time frame: Within 10 minutes prior to watching the film sequence, directly (within 5 minutes) after the film sequence, directly (within 10 minutes) after doctor-patient communication
Influence on concentration (Concentration task)
Time frame: Directly (within 10 minutes) after the pill was offered
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jun 2017.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Winfried Rief, PhD, Prof principal investigator
Philipps University Marburg
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Patient-centered style of communication and Doctor-centered style of communication in people with Healthy, run by Philipps University Marburg at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jun 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pill intake (time frame: Within 10 minutes after doctor-patient communication). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jun 2017.